169 related articles for article (PubMed ID: 36980628)
1. Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Culine S; Harter V; Krucker C; Gravis G; Fléchon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Fontugne J; Allory Y; Pfister C;
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980628
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
3. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Pfister C; Gravis G; Fléchon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Soulié M; Allory Y; Harter V; Culine S;
J Clin Oncol; 2022 Jun; 40(18):2013-2022. PubMed ID: 35254888
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Culine S; Harter V; Gravis G; Fléchon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Abadie-Lacourtoisie S; Geoffrois L; Fiore FD; Roubaud G; Barthélémy P; Voog E; Emambux S; Serrate C; Saldana C; Nguyen-Tan-Hon T; Loriot Y; Eymard JC; Huillard O; Rolland F; Houédé N; Spano JP; Demery ME; Vieillot S; L'Haridon T; Hilgers W; Allory Y; Pfister C;
Clin Genitourin Cancer; 2021 Dec; 19(6):554-562. PubMed ID: 34602349
[TBL] [Abstract][Full Text] [Related]
5. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C; Gravis G; Flechon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Soulie M; Allory Y; Harter V; Culine S;
Lancet Oncol; 2024 Feb; 25(2):255-264. PubMed ID: 38142702
[TBL] [Abstract][Full Text] [Related]
6. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial.
Pfister C; Harter V; Allory Y; Radvanyi F; Culine S;
Contemp Clin Trials Commun; 2020 Mar; 17():100536. PubMed ID: 32083220
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
8. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
[TBL] [Abstract][Full Text] [Related]
9. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
[TBL] [Abstract][Full Text] [Related]
10. Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data.
Joyce DD; Wymer KM; Sharma V; Moriarty JP; Borah BJ; Geynisman DM; Plimack ER; Costello BA; Pagliaro LC; Boorjian SA
Cancer; 2022 Dec; 128(24):4194-4202. PubMed ID: 36251574
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
12. Comment on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: Results of the GETUG-AFU V05 VESPER trial.
Ye JJ; Ren SQ; Bao YG
Asian J Surg; 2023 Feb; 46(2):1163-1164. PubMed ID: 36088195
[No Abstract] [Full Text] [Related]
13. Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
Mitsui Y; Okawa M; Hori S; Uetani M; Kasahara M; Yamabe F; Kobayashi H; Nagao K; Nakajima K
Int J Urol; 2024 May; ():. PubMed ID: 38819073
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
[TBL] [Abstract][Full Text] [Related]
16. Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities.
Ruplin AT; Spengler AMZ; Montgomery RB; Wright JL
Clin Genitourin Cancer; 2020 Oct; 18(5):e557-e562. PubMed ID: 32201105
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
van de Putte EE; Mertens LS; Meijer RP; van der Heijden MS; Bex A; van der Poel HG; Kerst JM; Bergman AM; Horenblas S; van Rhijn BW
World J Urol; 2016 Feb; 34(2):157-62. PubMed ID: 26184106
[TBL] [Abstract][Full Text] [Related]
18. Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.
Allory Y; Culine S; Krucker C; Fontugne J; Harter V; Pfister C
J Urol; 2024 Apr; 211(4):564-574. PubMed ID: 38153961
[TBL] [Abstract][Full Text] [Related]
19. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
Ravi P; Pond GR; Diamantopoulos LN; Su C; Alva A; Jain RK; Skelton WP; Gupta S; Tward JD; Olson KM; Singh P; Grunewald CM; Niegisch G; Lee JL; Gallina A; Bandini M; Necchi A; Mossanen M; McGregor BA; Curran C; Grivas P; Sonpavde GP
BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949
[TBL] [Abstract][Full Text] [Related]
20. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
